GlassScriptPhysician profile
Phillip B Land
NPI 1942378617
$2,492.13
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,188 · 2022: $1,233 · 2023: $71.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $71.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $71.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $361.60 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.64 | 2021-2023 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $138.34 | 2022 | |
| Lilly USA, LLC | $137.95 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $135.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $128.30 | 2021-2022 | |
| Novo Nordisk INC | $110.67 | 2021-2022 | |
| Glaxosmithkline, LLC. | $107.33 | 2021-2022 | |
| Pfizer INC. | $106.99 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $98.40 | 2021-2022 | |
| Forte Bio-Pharma LLC | $93.04 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.82 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.87 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $65.34 | 2021-2022 | |
| Amarin Pharma, INC. | $61.33 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $52.72 | 2023 | Proclaim |
| Amgen INC. | $42.17 | 2021-2022 | |
| Indivior INC. | $40.48 | 2021-2022 | |
| Alkermes, INC. | $37.73 | 2022 | |
| Sunovion Pharmaceuticals INC. | $34.93 | 2022 | |
| Scilex Pharmaceuticals INC. | $33.69 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $30.01 | 2021-2022 | |
| Mylan Specialty L.P. | $28.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.71 | 2022 | |
| Neurocrine Biosciences, INC. | $26.58 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.28 | 2022 | |
| Eisai INC. | $25.85 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $25.73 | 2021 | |
| Biogen, INC. | $25.11 | 2021-2022 | |
| Boston Scientific Corporation | $21.64 | 2022 | |
| Virtus Pharmaceuticals LLC | $16.61 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.77 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.21 | 2022 | |
| Daiichi Sankyo INC. | $14.01 | 2021 | |
| Corium, LLC | $13.22 | 2022 | |
| Merck Sharp & Dohme LLC | $12.71 | 2021 | |
| Paratek Pharmaceuticals, INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Land listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.